Eli Lilly’s launch of tirzepatide will strengthen its T2D market share
According to studies, Eli Lilly’s tirzepatide is expected to gain significant market share in the T2D market due to its…
By
Business & Regulation
Latest in
Business & Regulation
Joe Biden’s global corporation tax deal: A prediction on what’s next
Why have the nations of the world agreed to a new minimum corporation tax rate? And what happens to so-called…
By
Why has the WHO asked governments to delay Covid-19 booster jabs?
While booster shots will likely be needed long-term, the WHO has argued that first jabs for poorer nations should be…
By
Amgen’s Otezla wins patent battle, but a marketing war may await
Amgen has announced that it has won in a court ruling for the patent of Otezla, although commercial pressure may…
By
Waning Covid-19 vaccine efficacy: what does the data show?
While Covid-19 vaccines’ protection does appear to wane, most experts agree that universal booster rollouts aren’t needed yet.
By
Insurers to squeeze JAK inhibitor access in chronic conditions after FDA safety warning
A recent safety warning added by the FDA to JAK inhibitors approved for inflammatory conditions may mean increased payer pushback.
By
Multiple myeloma: first bispecific mAb to secure r/r approval will have biggest market bite
Market latecomers will likely struggle to demonstrate value-added edge so early strategic decisions are critical.
By
Novavax Covid-19 vaccine booster: safety and manufacturing questions remain
Novavax’s Covid-19 vaccine could find its niche as a booster shot, but questions linger around its safety and production.
By